Therapy-related long-term effects in childhood posterior fossa tumors by Gheysen, Mathilde et al.
Therapy-Related Long-Term Effects in Childhood Posterior Fossa Tumors
Gheysen Mathilde1,2, Sleurs Charlotte1,2*, Jacobs Sandra1,2, Lemiere Jurgen1 and Uyttebroeck
Anne1,2
1Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Belgium
2Department of Oncology, KU Leuven University, Belgium
*Corresponding author: Charlotte Sleurs, Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Belgium, Tel:
0032/16343991; E-mail: charlotte.sleurs@kuleuven.be
Rec Date: February 15, 2018; Acc Date: March 21, 2018, 2018; Pub Date: March 24, 2018
Citation: Mathilde G, Charlotte S, Sandra J, Jurgen L, Anne U (2018). Therapy-Related Long-Term Effects in Childhood Posterior Fossa Tumors. J
Neurol Neurosci Vol.9: No.2: 252.
Abstract
Background: Posterior fossa tumors constitute 60-70% of
central nerve system tumors in children. These are
localized in the cerebellum and the brain stem. The most
common tumor types are medulloblastoma, astrocytoma
and ependymoma. Treatment for these life-threatening
neoplasms is established mainly according to the tumor
type and can consist of surgery, radiotherapy and
chemotherapy. Since survival rates have significantly
increased during the last decades, long-term therapy-
related effects have become more and more important.
This study aims to give an extensive review of all
treatment-related long-term sequelae in posterior fossa
tumor survivors.
Method: The PubMed/Medline database was screened
for articles published in 1990-2017 using the following
search algorithm: ("Infratentorial Neoplasms"(Mesh) OR
cerebellar tumor OR brain stem tumor) AND
("Child"(Mesh) OR "Infant"(Mesh) OR
"Adolescent"(Mesh)) AND treatment AND (long term
sequelae OR outcome). Studies including only adult
patients or patients currently in treatment, studies not
covering long-term effects and non-original research
articles were excluded.
Findings: The search algorithm returned 1367 articles.
After a full screening procedure, 66 studies were retained
for the qualitative analysis. The most frequent long-term
sequelae were neurological complications, endocrine
deficits, speech problems and intellectual impairment.
Medulloblastoma patients suffered the greatest therapy-
related morbidity. Other important risk factors for worse
long-term outcome were radiation dose, radiation
volume, preoperative hydrocephalus and younger age at
diagnosis.
Conclusion: Therapy-related long-term effects are very
frequent in all posterior fossa tumor survivors and
comprise a broad spectrum of somatic,
neuropsychological and psychosocial issues. Therefore, all
caregivers involved should be aware of these sequelae, to
maximally support vulnerable children who survived their
cancer.
Keywords: Chemotherapy; Posterior fossa tumors;
Sequelae; Cranial radiotherapy;
Introduction
Central nervous system (CNS) tumors are the most common
solid neoplasms in children [1-3]. These tumors also represent
the second most common malignancy during childhood,
preceded by leukemia [1,4] and the most common cause of
death from solid tumors [1]. 60-70% of CNS tumors in children
occur in the posterior fossa [3]. These posterior fossa tumors
cover a heterogeneous group of tumor types, localized in the
infratentorial compartment of the brain, more specifically the
cerebellum and the brain stem [5]. The most prevalent types
of posterior fossa tumors in children are medulloblastoma,
cerebellar pilocytic astrocytoma, ependymoma, atypical
teratoid rhabdoid tumor (ATRT) and brainstem glioma [1,3,6].
Acute symptoms of posterior fossa tumors in children are
mainly the result of increased intracranial pressure, due to the
mass effect of the tumor and obstructive hydrocephalus.
Therefore, patients often present with headaches, nausea,
emesis and cranial neuropathies causing extra-ocular muscle
disorders. Signs of cerebellar derangement, such as ataxia and
dysmetria are also frequent [1,7]. Brain stem involvement,
caused by brainstem gliomas or other posterior fossa tumors
invading the brain stem, induces specific brainstem symptoms.
These include pyramidal tract signs such as hemi- or
quadriparesis, ataxia, dysmetria, swallowing problems and
impairment of multiple cranial nerves such as the oculomotor,
trochlear, abducens and the facial nerve [1,8].
When such alarming symptoms occur, imaging is the next
step to define the diagnosis. Although CT-scans can be helpful
in emergency situations to make a quick preoperative
evaluation, MRI is the preferred imaging technique to
determine the tumor extent, to provide arguments for the
most suitable treatment plan and to evaluate treatment
Research Article
iMedPub Journals
www.imedpub.com
DOI: 10.21767/2171-6625.1000252
Journal of Neurology and Neuroscience
ISSN 2171-6625
Vol.9 No.2:252
2018
© Copyright iMedPub | This article is available from: 10.21767/2171-6625.1000252 1
response later [1]. Furthermore, MRI-modalities such as
diffusion weighted imaging, MR spectroscopy and MR
perfusion have been shown valuable in discriminating
between the histologic tumor types before pathological
confirmation is accomplished [6,9]. Craniospinal MRI is the
golden standard to detect dissemination in the cerebrospinal
fluid [1]. Histological typing of the tumor is performed during
pathological examination of the resection species. A biopsy is
only acquired if surgery is impossible [3]. For instance, in
diffuse intrinsic pontine glioma, stereotactic biopsy is currently
recommended. These findings provide a gateway to
developing targeted therapies in this aggressive tumor type
[10].
Once the diagnosis is determined, an individualized
treatment plan is to be established. Currently, three important
treatment modalities are applied for posterior fossa tumors:
surgery, radiotherapy and chemotherapy. A combination of
these three modalities is administered according to the tumor
type, localization and age at diagnosis. First, surgical resection
is included in all treatments. However, precarious tumor
localization (e.g. in the brain stem) can make a resection
impossible [8]. Other specific surgical treatments (an external
ventricular drain, a ventriculoperitoneal shunt or a third
ventriculostomy) are often performed to reduce intracranial
pressure in case of hydrocephalus [8,11,12]. Second,
radiotherapy is indispensable for some tumor types.
Medulloblastoma patients receive craniospinal radiotherapy
with posterior fossa boost [11,13], whereas in astrocytoma
radiotherapy is exceptionally added in children with
progressive and inaccessible tumors [12]. Ependymoma
patients receive postoperative 3D conformal radiation therapy
to the tumor bed [14,15]. Although radiotherapy is very
effective, age at diagnosis is an important factor to consider.
Radiotherapy is usually avoided in patients younger than three
years, due to the deleterious impact on the developing brain
[3]. Finally, the alternative treatment option for fossa posterior
tumors is adjuvant chemotherapy, for which administration
mainly depends on the tumor histology. In medulloblastoma,
postoperative chemotherapy is the standard of care [13],
while in astrocytoma it is only first line therapy if resection is
impossible [12]. In ependymoma, only patients younger than
three years of age are treated with chemotherapy, albeit not
always effective [14].
Cancer treatment can lead to acute as well as long-term
symptoms. A well-known acute consequence of cerebellar
surgery is the posterior fossa syndrome (PFS). This syndrome
appears in 25% of children after tumor resection in the
posterior fossa. The syndrome comprises distressing symptoms
[5], postoperative mutism [16], ataxia, hypotonia, emotional
lability and behavioral symptoms. Recovery of PFS is slow and
often incomplete. As a result, the syndrome is associated with
potential long-term symptoms including reading deficits, lower
intellectual ability, poor academic and cognitive outcomes,
psychosocial complaints, neurologic deficits and lower quality
of life (Qol) [5].
Due to the heterogeneity of fossa posterior tumors and
their treatment, prognosis is also very variable. The prognoses
for medulloblastoma and ependymoma patients are
moderate, with 5-year survival rates of approximately 70% and
60%, respectively. Astrocytoma patients have the best
prognosis, with a 90% 5-year survival rate [3]. This contrasts
strongly with the dismal outlook of ATRT patients, with only
29.9% 5 year survival [17]. Finally, DIPG patients suffer the
worst prognosis: the mean overall survival is 11 months and
the 5-year overall survival is 2% [8,18-21].
Since survival rates for medulloblastoma, ependymoma and
astrocytoma have significantly increased during the last
decades [3], long-term therapy-related sequelae receive more
and more attention. These sequelae could include somatic
(e.g. endocrine problems [2,11,21], second neoplasms [11,21],
kyphosis and vertebral demineralization [11]),
neuropsychological (e.g. motor speech deficits [22],
intellectual impairment, attention deficits, memory difficulties
and executive dysfunction [3,4,11]) and psychosocial issues
(e.g. unemployment, incapacity to drive and lower Qol [21]).
A bulk of research exists for the different domains of long-
term deficits of posterior fossa tumor survivors. To our
knowledge, a systematic review of long-term symptoms from
which these children can suffer throughout life, is missing.
Therefore, this study aims to give a comprehensive and an
integrated overview of all long-term sequelae (including
somatic, neuropsychological and psychosocial outcomes)
related to posterior fossa tumor therapy in children. A second
aim is to link the various treatment types to specific long-term
sequelae.
Methods 
The PubMed/Medline database was screened using the
following search algorithm: ("Infratentorial Neoplasms"(Mesh)
OR cerebellar tumor OR brain stem tumor) AND
("Child"(Mesh) OR "Infant"(Mesh) OR "Adolescent"(Mesh))
AND treatment AND (long term sequelae OR outcome). Two
additional filters were applied including: date of publication in
1990-2017 and English as publication language. Records were
included if long-term somatic, long-term neuropsychological
and long-term psychosocial effects of posterior fossa tumor
survivors were depicted. Studies were excluded in case of in
vitro or animal studies, also studies with patients >18 years
who did not receive treatment during childhood, studies
including current patients (i.e. if >50% of study population was
followed <2 years after cancer diagnosis), studies covering
other diagnoses (i.e. non-cancer or other types of cancer),
non-original-research articles (case reports, expert opinions,
conference summaries) and articles not reporting long-term
effects. Duplicates were removed from the dataset. Studies
were divided into three categories (medical,
neuropsychological and psychosocial effects) and related to
the treatment modality (surgery, chemotherapy and
radiotherapy).
Results
The literature search returned 1369 articles, which were
screened systematically. Stepwise amounts of included/
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excluded articles are shown in the flowchart below (Figure 1),
according to PRISMA guidelines. After removal of duplicates
(n=2), the first selection was based on screening of the titles,
eliminating 857 titles. Next, articles were screened for
eligibility based on the abstracts, which resulted in 75
remaining studies for full-text screening. 7 studies were
excluded, since full text was not available. Subsequently, each
included record was classified into one of the categories
mentioned above. 16 of the included articles described
somatic symptoms, 39 articles reported on neuropsychological
long-term effects, 3 articles covered psychosocial issues and 9
studies reported on all these effects. Two articles were
excluded after analysis of the full text. Characteristics of the
included studies are represented in Table 1, as well the
number of articles describing long-term effects of each
treatment modality.
Surgery-induced symptoms
Long-term effects related merely to surgery, have only
recently gained interest. The most frequently investigated
patient population to study these effects are cerebellar
pilocytic astrocytoma patients, because their treatment often
consists of surgery only.
Surgery-related somatic effects: Nagib et al. reported
permanent lower cranial nerve dysfunction in 2 of the 4
included patients after surgery for posterior fossa lateral
ependymoma, a rare type of ependymoma [23]. The effects of
surgery on general brainstem functions in ependymoma
patients were studied by Merchant et al. They conducted a
long-term neurological follow-up in 64 ependymoma patients
treated with surgery and conformal radiotherapy (54–59.4 Gy).
23 patients experienced incomplete brain stem recovery after
5 years, defined as impaired function of cranial nerves V-VII
and IX-XII, motor weakness and dysmetria.
Figure 1 Flowchart of included studies.
Table 1 Included articles. Note: The included articles were classified into the different treatment modalities, categories of long-
term sequelae and tumor types. Several articles described multiple types of long-term effects. RT: Radiotherapy, Chemo:
Chemotherapy, MB: Medulloblastoma.
Treatment #
Articles
#
Patients
(ranges)
Somatic Neuropsychology Psychosocial MB Ependymoma Astrocytoma Multiple
Surgery 17 4-203 5 10 2 1 1 9 6
RT 33 7-151 15 18 2 27 0 0 6
Chemo 1 21-35 1 0 0 1 0 0 0
Surgery +RT
+Chemo
15 16-137 4 15 2 7 2 0 6
Total 66 4-203 16 38 3 36 3 9 18
These neurological outcomes depended on surgical
variables such as CSF shunting, the number of interventions
(resection and shunting), the extent of resection and tumor
volume [24]. Variations in brainstem radiation dose (range 54–
59.4 Gy) and volume did not impact the outcome. Another
study of Schoch et al. depicted the balance function in 22
patients treated for benign and malign posterior fossa tumors
in childhood. More specifically, this study compared patients
with and without affected cerebellar nuclei and patients with
and without adjuvant therapy (chemotherapy and/or
radiotherapy). The authors concluded that surgical damage of
the deep cerebellar nuclei, especially the fastigial nucleus was
responsible for balance impairment in these patients [25].
Zuzak et al. reviewed multiple long-term effects in 21
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cerebellar astrocytoma survivors. Neurological deficits (limb
ataxia, truncal ataxia, dysarthria, and ocular movement
disorders) occurred frequently (41%, n=9) [26]. Similarly,
Villarejo et al. retrospectively reviewed 203 astrocytoma
survivors. Most of these patients exhibited no neurological
deficits (55%). Some of them (27%) had mild neurological
deficits (strabismus, nystagmus or ataxia) without psychosocial
implications, while a few survivors (4%) were severely disabled
and incapable of leading a normal life [27].
Surgery-related neuropsychological effects: Four records
covered the neuropsychological consequences of pilocytic
astrocytoma surgery in childhood. 201 adolescents and adults
were included. Although most of these patients obtained a
normal intelligence quotient and close to normal academic
achievements, milder neuropsychological deficits were
reported in 57-100% of them. These deficits included:
dysarthria, difficulties in sustained attention, visuospatial
capacities, executive functioning, memory, processing speed,
behavioral problems, psychiatric symptoms [28-32]. Special
education was needed in 11-24% of patients [28,29]. Beebe et
al. (n=103) found little effect of tumor localization on these
deficits [30], whereas Steinlin et al. claimed that vermis
involvement was associated with more neuropsychological
problems (n=24) [31].
In another study of Grill et al., perioperative risk factors of
intellectual impairment were reviewed in 76 patients treated
for malignant posterior fossa tumors. Average verbal
intelligence quotient (VIQ) was in the lower average range
(86.9 ± 18.9), whereas performance intelligence quotient (PIQ)
was subnormal (75.8 ± 17.5). Preoperative hydrocephalus,
vermis incision and neuropsychological the amount of
postoperative cerebellar damage was significantly related to
lower IQ scores [33]. Puget et al. also highlighted the effect of
surgical cerebellar nuclei damage in 61 children treated for
malignant posterior fossa tumors. Damage of the dentate
nuclei and the inferior vermis was related to lower intellectual
outcome than patients without this damage, after correction
for other risk factors (radiation, hydrocephalus, surgical
complications…) [34]. Not only cognitive and affective
symptoms define the spectrum of long-term
neuropsychological outcome. Also, speech can be affected.
Four studies explored long-term speech deficits in 56 patients
(astrocytoma n=25, medulloblastoma n=29, ependymoma
n=2) following surgery. Most patients who experienced
postoperative cerebellar mutism also encounter cerebellar
dysarthria, slower speech and dysfluency in the long-term
[35,36], but results are somewhat inconclusive for patients
without postoperative mutism. Huber et al. found no
difference in speech capacities between patients without
postoperative mutism and healthy controls [35]. On the
contrary, De Smet et al. and Morgan et al. both found higher
percentages of long-term speech deficits (e.g. distorted
vowels, slow rate, voice tremor) even in patients without
postoperative cerebellar mutism [37,38].
Surgery-related psychosocial effects: Psychosocial effects
associated with surgery were investigated by Zuzak et al. [26].
The authors evaluated 21 cerebellar astrocytoma survivors, of
whom 33% (n=7) had behavioral problems and 19% (n=4)
required special education due to cognitive deficits. However,
most of them were still capable to perform normal daily life
activities and their health-related Qol was rated like or even
higher than controls. Apparently, these objective deficits had
only minor influence on the subjective Qol [26]. These findings
were nuanced by Pompili et al. who described Qol in 20 adults
treated for cerebellar astrocytoma in childhood compared to
20 matched controls. They used two Qol questionnaires: the
KPS and a detailed QoL questionnaire. These adult survivors
had normal global functioning (as indicated by the KPS) and
can lead a normal life, consistently with the findings of Zuzak
et al. However, using the more profound Qol questionnaire,
they had significant lower satisfaction than the control group
when it came to social contacts, cognition, memory, well-being
and adolescence [39].
Radiotherapy-related somatic effects
All articles describing long-term somatic effects related to
radiotherapy, considered medulloblastoma survivors only.
Eight of these studies explored long-term endocrine sequelae
in 339 patients treated with postoperative craniospinal
radiotherapy (doses ranging from 18 to 39 Gy craniospinal and
18-60 Gy posterior fossa boost). The most frequent endocrine
long-term effects found in these studies included growth
hormone (GH) deficiency and both primary and secondary
thyroid dysfunction. GH deficiency leads together with spinal
radiation to diminished adult height [40-46]. According to
Kennedy et al. hyperfractionated radiotherapy (n=74) resulted
in worse growth compared to conventional radiotherapy
(n=77) [47]. Also, regarding GH deficiency, starting GH
hormone administration at younger age resulted in better
growth outcomes [44]. Helseth et al. studied the long-term
outcome of 34 medulloblastoma survivors, treated with 35 Gy
craniospinal radiation and 20 Gy posterior fossa boost. They
found diminished height in most patients and the need of
hormonal therapy in 50% of patients [48]. Also,
Christopherson et al. followed up 53 medulloblastoma patients
treated with a median craniospinal dose of 28.8 Gy and a
posterior fossa or tumor bed boost of 25 Gy. The most
important long-term effect of craniospinal radiotherapy was
growth suppression (61.5% of patients). Less frequent
endocrine sequelae were adrenal insufficiency, hypogonadism
and precocious puberty [46]. These long-term effects could
manifest up to 15 years post-treatment and were more
prevalent in patients treated with chemotherapy (cisplatin,
vincristine and lomustine) [45]. Symptoms also appeared to be
dose-dependent [46].
A second important long-term somatic effect related to
radiotherapy is the development of secondary neoplasms. This
was illustrated in several studies with a total of 167 included
patients, who were all treated with craniospinal radiotherapy
for medulloblastoma. Malign neoplasms included breast
cancer, thyroid cancer, lung cancer, stomach cancer, basal cell
carcinoma and glioblastoma multiforme. Benign neoplasms
described were meningiomas and cavernomas [49-52]. Helseth
et al. showed second neoplasms in 14% of of 34
medulloblastoma survivors.
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Intensity modulated proton therapy (IMPT), one of the more
recent radiotherapy techniques, was associated with a lower
risk of secondary neoplasms compared to 3D conformal
radiotherapy (CRT) [49]. One study made a risk estimation of
developing secondary malignancies after conventional
craniospinal radiotherapy, IMPT and another technique called
inversely-optimized arc therapy (RA). They made hypothetical
treatment plans for the three techniques in 10
medulloblastoma survivors who already received craniospinal
radiotherapy. The life time risk of a solid secondary neoplasm
was estimated the highest in RA, the lowest in IMPT and
increased with higher radiation dose. However, these
estimations were merely based on predictive modeling. Exact
data were missing [52].
Sporadically, hearing loss was observed in medulloblastoma
patients, due to radiation-induced serous otitis media and
sensorineural damage, skull radio necrosis, and cerebral
ischemia or aneurysm development [53]. According to Kiltie et
al. children treated with craniospinal radiotherapy under three
years of age experienced similar problems, albeit to a higher
degree than older patients. Furthermore, 75% of these
younger patients suffered from severe neurologic late effects
as ataxia, epilepsy, cranial nerve deficits and blindness [54].
Radiotherapy-related neuropsychological effects:
Neuropsychological dysfunction is the most extensively
investigated long-term effect in posterior fossa tumor
survivors. Most patients participating in these studies are
medulloblastoma survivors treated with craniospinal
radiotherapy. Nevertheless, ependymoma and astrocytoma
patients were also occasionally included. Both high (range
30.6-41.4 Gy) and reduced doses (range 18-25.2 Gy) of
craniospinal radiotherapy were applied. Posterior fossa boost
dose was ranged between 12.6 and 60 Gy, tumor bed boost
between 16 and 86 Gy. The most frequently assessed outcome
was intelligence, objectified by the Wechsler scale of
intelligence (population mean=100, SD=15). George et al.
studied long-term general cognitive sequelae for
medulloblastoma and astrocytoma survivors (n=15). The mean
full-scale intelligence quotient (FSIQ), VIQ, and PIQ were all
significantly lower than the normal population, as were verbal,
visual and general memory. There was no significant difference
between VIQ and PIQ. Verbal and visual memory were also
equally affected. Younger age at diagnosis (<6 years) resulted
in lower long-term IQ scores than older age [55]. A study of
Mabbott et al. specifically compared patients treated with
surgery and cranial radiation and patients who received
surgery only. Both cranial radiation and postsurgical
complications were related to lower IQ and information
processing speed. Age at diagnosis was not a predictor for
these problems [56]. According to Abd El-aal et al., the
addition of postoperative chemotherapy (vincristine,
etoposide and cisplatin) had no effect on cognitive outcome
[57].
The evolution and determinants of this intellectual decline
were investigated in three studies, including 191
medulloblastoma and 9 ependymoma survivors treated with
23.4 or 35-40 Gy craniospinal radiation [58-60]. IQ declined
year after year (1.70-2.05 points per year) [58,60], as well as
academic achievement [60]. Higher baseline intelligence was
associated with steeper intellectual decline [58-60]. Younger
age at diagnosis also resulted in steeper decline in two of the
three records [59,60]. This effect of age at diagnosis was
confirmed by Rutkowski et al. These researchers observed 29
children with medulloblastoma diagnosed younger than three
years old. 12 of them relapsed during chemotherapy and were
administered 24 Gy craniospinal radiotherapy with a boost on
the metastases. These patients had very low intellectual
outcome 6.1 years after diagnosis (IQ 77.7 ± 7.2) [61].
The mechanism of radiation-induced intellectual
deterioration could be found in both volume reduction and
microscopic injury of white matter. Three studies investigated
brain damage after craniospinal and posterior fossa boost
radiotherapy with diffusion tensor MRI imaging (DTI). In a
record of Riggs et al. irradiated medulloblastoma and
astrocytoma survivors (n=20) exhibited reduced white matter
volume compared to healthy controls (n=13). The fasciculus
uncinatus and the right hippocampus were the most affected
areas. Volume reductions resulted in lower memory scores
[62]. Additionally, Mabbott et al. (n=8) and Law et al. (n=29)
focused on apparent diffusion coefficient (ADC) and fractional
anisotropy (FA). Craniospinal radiotherapy was associated with
increased ADC and decreased FA of white matter. If the
cerebello-thalamo-cerebral connections were affected by
these changes, this was associated with poor intellectual
outcome and working memory [63,64]. Similarly, a study of
Wilburn confirmed reduced white matter in pediatric brain
tumor survivors to be associated with lower IQ and academic
achievements [65].
Extensively analyzed characteristics of intellectual decline
are the influence of radiation volume and dose-dependency.
This was illustrated in four studies comparing posterior fossa
or tumor boost radiotherapy (45-55.4 Gy) without craniospinal
radiotherapy, with reduced dose (15-25 Gy) and with standard
dose craniospinal radiotherapy (30.6-39 Gy) in 184 patients. All
these studies concluded that local radiotherapy resulted in
smaller decrease in FSIQ than craniospinal radiotherapy.
Furthermore, higher craniospinal doses were associated with
greater decrease in FSIQ [59,66-68]. Moxon-Emre et al. also
added that higher boost volumes (posterior fossa boost vs.
tumor bed boost), hydrocephalus and postoperative mutism
resulted in poorer intellectual outcome [67].
Besides radiation dose, genetics could also influence the risk
of radiation induced brain injury, as postulated by Bracket et
al. The childhood cancer survivor study neurocognitive
questionnaire and the Brief Symptom Inventory of 109
medulloblastoma patients were compared to 143 healthy
siblings. Polymorphisms in multiple antioxidant enzymes
(SOD2, GPX1, GSTP1, GSTM1, GSTT1) were determined in both
groups. Medulloblastoma survivors scored significantly worse
on memory and task efficiency, the latter even more impaired
in children <7 years at diagnosis. Globally these findings were
independent of the investigated polymorphisms. However, a
subgroup of survivors with homozygous GTMS 1 experienced
significantly more anxiety, depression and global distress [69].
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Finally, modern radiotherapy methods have received
attention only more recently. Jain et al. showed that there was
no difference in cognitive decline between IMRT and
conventional radiotherapy in 25 medulloblastoma patients
[70]. Similarly, FSIQ in standard risk medulloblastoma patients
treated with HFRT (n=71) did not significantly differ from
patients treated with conventional radiotherapy (n=66) [71].
Additionally, Kennedy et. al even showed improved executive
functioning in patients treated with hyperfractionated
radiotherapy, compared to conventional radiotherapy [47].
Radiotherapy-related psychosocial effects: Radiotherapy
for posterior fossa tumors can lead to serious psychosocial
problems. Helseth et al. found psychosocial impairments
(learning abilities, sociability, hobbies, relations) in 62% of the
34 medulloblastoma survivors [48]. This was also previously
investigated in a study of Mabbott et al. This record included
53 posterior fossa tumor survivors (46 medulloblastoma
patients and 7 ependymoma patients). 48 patients were
treated by craniospinal radiation (23.4-41.6 Gy) with a
posterior fossa boost (45.0-55.8 Gy). They were evaluated with
standardized achievement tests as well as parent and teacher
questionnaires. Three years post-diagnosis, school skills and
academic achievement were about one standard deviation
below the population average. Hydrocephalus and younger
age at diagnosis were associated with poorer academic
outcome, whereas radiation dose, extent of resection and use
of chemotherapy were not. Behavioral problems were only
mild. A longitudinal analysis (median follow-up after diagnosis
4.84 years for academic achievement and 4.17 years for
behavioral function) revealed that academic skills continued to
decline over time. Behavior remained rather stable according
to parent questionnaires. However, some showed social
withdrawal and attention problems after a few years [72].
Chemotherapy-induced effects
Chemotherapy-induced somatic effects: This review only
returned one article describing a well-known consequence of
chemotherapy in medulloblastoma surivors, being hearing
loss. Lafay-Cousin et al. acquired audiograms in 35 children
during and after cisplatin treatment for average risk (AR) and
high risk (HR) medulloblastoma patients. AR patients received
higher doses of cisplatin (412.5 mg/m2 vs 270 mg/m2),
whereas HR patients received higher doses of craniospinal
radiotherapy (36-39 Gy vs 23.4 Gy). Both AR and HR patients
often required hearing support five years after treatment.
However, the AR group more frequently required dose
reduction of cisplatin during treatment due to hearing loss.
This finding suggests that the effect of higher cumulative dose
of cisplatin exceeds the damage of a higher radiation dose in
the short term. However, this difference disappears over time
[73].
Combined therapies
Somatic effects: Multiple included studies (n=145 patients
in total, mostly medulloblastoma patients) depicted different
types of long-term effects of different treatment regiments
(surgery, craniospinal radiotherapy with or without
chemotherapy). All of them could confirm the
abovementioned results. Endocrine deficits, neurologic
sequelae, hearing loss and academic difficulties were very
frequent in all of these studies [21,74-76].
Neuropsychological effects: As could be inferred from
abovementioned studies, each treatment constituent might
cause long-term effects in childhood posterior fossa tumors.
Many additional studies investigated the effects of combined
treatments. Von Hoff et al. and Chapman et al. investigated
the influence of radiotherapy and surgery on
neuropsychological outcome [77,78]. They evaluated
intelligence scores in 23 ependymoma survivors treated with
surgery and posterior fossa boost radiotherapy (mean 54 Gy).
PIQ was significantly lower than normal, whereas FSIQ, VIQ
were only moderately impaired. All patients experienced
reading difficulties. However, no decline in IQ scores was
notified in a longitudinal analysis. Factors associated with
lower IQ included the posterior fossa syndrome, preoperative
hydrocephalus and radiation volume. Again, younger age at
irradiation resulted in lower neuropsychological outcome [77].
In the record of Chapman et al. 13 medulloblastoma and 2
ependymoma patients were included. The radiotherapy
protocols consisted of high radiation doses, also in children
under three years of age. Younger age at diagnosis and
perioperative issues (preoperative hydrocephalus, resection of
neocerebellum tissue) were once more associated with worse
outcome, but also with a higher incidence of obtundation at
diagnosis [78]. This effect of age at diagnosis was once more
confirmed by Edelstein et al. [74] and Johnson et al. [79].
The above-mentioned general studies considering somatic
long-term effects, also reported on neuropsychological effects.
Not surprisingly, neuropsychological issues were a major
problem in most medulloblastoma survivors [21,74-76].
Huber et al. studied long-term speech deficits in both
astrocytoma and medulloblastoma survivors. All experienced
dysfluent speech, but atactic dysarthria and slow speech were
only frequent in medulloblastoma survivors [22]. In a record of
Szathmari et al. speech deficits in medulloblastoma survivors
could be predicted by tonsillar herniation and a larger tumor
volume on preoperative MRI [80]. Other neuropsychological
differences between medulloblastoma and astrocytoma
survivors were described by Roncadin et al. and Ronning et al.
As expected, medulloblastoma survivors clearly scored worse
on several outcome scales (memory, intelligence, attention)
than astrocytoma survivors [81,82]. In both studies, younger
age at diagnosis predicted lower cognitive functioning in
medulloblastoma survivors. The important contribution of
craniospinal radiotherapy on cognitive decline was confirmed
in a prospective study of 35 posterior fossa tumor survivors by
Stargatt et al. The previously described detrimental effect of
hydrocephalus was replicated in several studies [81,83,84].
This was less clear in astrocytoma survivors [81,82]. Finally,
Schreiber et al. added the presence of the posterior fossa
syndrome, hearing loss, and high-risk status as significant risk
factors for intellectual and academic decline in 165
medulloblastoma survivors, next to younger age at diagnosis
[85].
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Psychosocial effects: Kulkarni et al. investigated long-term
Qol in 62 survivors of different types of posterior fossa tumors
(medulloblastoma, astrocytoma and ependymoma).
Consistent with previous findings, Qol in those survivors was
not significantly lower than the general population. Risk
factors for lower scores included hydrocephalus and
socioeconomic status [86]. While Kulkarni et al. stated that
there was no difference in general Qol between the tumor
types, Ribi et al. noted that social functioning was lowest in
medulloblastoma survivors. Notably, parents rated Qol for
their children was lower than patients themselves [76].
Discussion
Treatment for posterior fossa tumors evolved impressively
over the last decades. This had led to improved survival rates
for children diagnosed with medulloblastoma, astrocytoma
and ependymoma. However, this positive trend also involves
the apparition of higher treatment-related symptoms. This was
extensively illustrated in the 66 articles included in this review.
First, surgery appears as responsible for neurologic symptoms
(ataxia, impaired balance and cranial nerve deficits) and mild
cognitive and psychosocial issues. Second, radiotherapy
(especially craniospinal radiotherapy) is related to a much
wider range of long-term sequelae. These include endocrine
deficits, secondary neoplasms, neurological sequelae such as
hearing loss, intellectual decline and severe psychosocial
problems (lower academic achievement and social
functioning). Third, chemotherapy was only associated with
hearing loss in this review.
As treatment modalities result in different sequelae, it is
evident that the long-term symptoms a survivor can
experience, highly depend on the treatment that was
administered. This in turn is determined by the tumor type.
However, tumor type possibly also influences baseline
performance (before initiation of therapy). Unfortunately, this
was insufficiently investigated sofar. Astrocytoma survivors
treated with surgery only can experience severe neurological
sequelae, but cognitive and psychosocial impairment seem
rather mild. On the contrary, medulloblastoma survivors suffer
the greatest from treatment-related morbidity due to the
burdensome combination of surgery, craniospinal radiotherapy
and chemotherapy. Logically, the results of ependymoma
survivors are situated somewhere in between.
When it comes to somatic long-term sequelae, surgery-
induced brain damage was most frequently related to
neurological symptoms include ataxia, impaired balance and
several cranial nerve deficits. The latter can cause ocular
movement disorders (n. III, IV, VI) [23,25-27]. Such symptoms
are probably due to damage to specific cerebellar nuclei,
particularly balance dysfunction [25].
Radiotherapy can also give rise to neurological symptoms
such as hearing loss (n. VIII) and even blindness (n. II) in severe
cases. Hearing loss can be induced both by this radiation-
induced serous otitis media or sensorineural damage and by
platinum-based chemotherapy [53,73]. Irradiation is known to
induce brain damage through multiple toxic mechanisms,
including vascular abnormalities, inflammation, gliosis,
demyelination and ultimately white matter necrosis [2,10,11]
and decreased neurogenesis [12]. From animal models we
know that oligodendrocytes decrease, leading to lower
myelination levels [13]. Also, vascular endothelial cells at the
blood-brain barrier are affected [14,15]. Another highly
relevant problem is endocrine impairment. This is caused by
radiation to the hypothalamic–pituitary axis and the thyroid
gland. The most common clinical manifestations are GH
deficiency, hypothyroidism (both primary and secondary),
adrenal insufficiency, hypogonadism and precocious puberty
[40-45,87]. Consequently, posterior fossa tumor survivors are
smaller than their peers, because of GH deficiency and spinal
radiation. These deficits are clearly dose-dependent [43].
While endocrine defects are very frequent (up to 50%), albeit
not life-threatening, the development of second neoplasms is
rarer (14%) but can be fatal [48]. Second neoplasms can occur
within the radiated area (meningiomas, cavernomas,
glioblastomas, thyroid cancer, basal cell carcinoma) or even in
areas not strictly localized in the radiation field (breast cancer,
lung cancer). These remote neoplasms were mostly seen in
older radiotherapy regiments with higher doses and larger
radiation fields [49-52]. Mortality is due either to the inherent
malignant character of the neoplasm, either to local
complications of the lesion (for instance bleeding of a
cavernoma) [49,50].
All these somatic inferences might affect daily life and
neuropsychological functioning of the patient. This is present
in all types of posterior fossa tumors, but obviously more
prominent in the medulloblastoma group. These children
exhibit clearly worse FSIQ, PIQ, VIQ, memory, nonverbal
intellectual functioning, processing speed and academic skills
than the normal population [55,69]. Furthermore, IQ
continues to decline [58,60]. Astrocytoma and ependymoma
survivors mostly encounter more subtle problems like reading
difficulties and slower processing speed, whereas IQ and
academic achievement remain most often normal [28-32,77].
Younger age at diagnosis results in lower cognitive outcome in
medulloblastoma and ependymoma survivors [77,78]. The
effect of younger age at diagnosis was less clear for
astrocytoma patients, with even better outcome in younger
patients [88]. This could be explained either by great neuronal
plasticity in a young brain unexposed to radiotherapy, or by
lack of testing sensitivity in younger children [88].
Preoperative hydrocephalus and postoperative surgical
complications (e.g. mutism, the posterior fossa syndrome,
damage of the dentate nuclei or vermis) also holds a risk of
greater intellectual disabilities and poorer academic outcome
in all posterior fossa tumors [34,67,81,85]. Important causes of
neuropsychological sequelae are underlying neuroanatomical
changes, especially radiation-induced neural atrophy and
microscopic damage of cerebral white matter [62-64]. This
could explain why somatic risk factors described above result
in greater intellectual decline, since they either directly induce
more white matter injury (higher radiation volume and dose,
hydrocephalus) or increase the susceptibility to radiation-
induced damage (younger age at diagnosis).
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Another disabling long-term related to neurological damage,
is speech impairment. Medulloblastoma as well as
astrocytoma survivors experience speech dysfluency. However,
atactic dysarthria and slow speech are only evident in children
treated for medulloblastoma. This indicates that irradiation
also has detrimental effects on the cerebellum, fronto-
cerebellar tracts, language and motor coordination [22,35-38].
It is not surprising that all these sequelae have a major
impact on the future lives of these patients. They all must deal
with multiple psychosocial issues, especially medulloblastoma
survivors. These patients frequently have a decline in school
skills (reading, mathematics, spelling), need special education,
and are unemployed. Hydrocephalus and younger age at
diagnosis result in poorer academic outcome. In astrocytoma
patients, these psychosocial issues are clearly less
pronounced. Considering Qol, social functioning was
recurrently lower. Despite difficulties in establishing and
sustaining relationships, global Qol of medulloblastoma,
astrocytoma and ependymoma survivors is often not reported
as lower than normal. This might signify that patients
eventually learn to cope with their disabilities, or might be
unaware of their symptoms [26,39,48,72,86].
Limitations
This study has several limitations. First, a quantitative
analysis could not be established due to great heterogeneity in
the included studies. These studies all included different
patient populations of different ages, often depicted multiple
risk factors and tumor subtypes (low risk and high risk). Also,
the exact radiotherapy doses of the cranial and the spinal
component of craniospinal radiation were usually not
specified. This impedes valuable conclusions in a meta-analysis
about dose dependency of symptoms and about distinctions
between cranial or spinal radiation doses. Secondly, most of
the included articles were older than 2010, given that recent
research focuses new therapies of which long-term effects
cannot be judged yet. Thirdly, the search algorithm did not
return many articles about chemotherapy-induced sequelae
only. The reason for this could be that chemotherapy was
added only quite recently and therefore it might still be too
early to evaluate its long-term effects. Finally, this literature
search covers a wide extent of symptoms. Given the large
number of screened articles through the entire procedure,
screening was only performed by one author. Due to limited
timing, no inter-observer reliability could be determined.
Future Directions
As somatic symptoms, and neurocognitive dysfunction
highly affects quality of life of posterior fossa tumor patients,
patients will require treatment adaptations, and early motor
and cognitive rehabilitation. Recently, the diagnostic approach
for brain tumors is dramatically changing. While the former
WHO classification of CNS tumors (2007) primarily categorized
the neoplasms according to histology, the most recent
classification (2016) is based on the combination of both
histological and genetics findings. As a result, formerly
recognized histological entities are subdivided into different
genetic subtypes. Medulloblastomas can now be assigned to
one of five genetic subgroups (WNT activated, SHH activated
TP53 mutated, SHH activated TP53 Wild Type, group 3 and
group 4) next to the pre-existing histological classification.
These strictly defined subgroups will most likely contain
greater prognostic value and will certainly be a guide line for
personalized CNS tumor therapy in the future [89,90].
Advanced MRI technique (dynamic contrast enhanced,
susceptibility weighted imaging, diffusion tensor imaging and
functional MRI) will be implemented more and more often for
maximal preoperative tumor characterization. Additionally,
11C-methionine PET has recently been shown useful in
discriminating between high grade and low-grade tumors. On
the other hand, intraoperative MRI (iMRI) is a promising
modality for evaluating the extent of resection during surgery
[7]. These new technologies will hopefully also contribute to a
more tailored treatment plan.
Treatment regiments are improving in order to reduce
neurotoxicity as well. Advances in radiation therapy, such as
intensity modulated radiation therapy (IMRT), intensity
modulated proton therapy (IMPT) and hyper fractionated
radiation therapy (HFRT), have recently been introduced in
posterior fossa tumor therapy. In HFRT, overall survival is like
standard craniospinal radiotherapy [91]. First results about
therapy-related sequelae were promising. HFRT was associated
with better long-term executive functioning compared to
conventional radiotherapy [47] but these results remain
limited and inconsistent [70,71]. IMRT could also result in less
hearing loss [92] and IMPT in lower risk of second neoplasms
[93]. Another recent development in treatment is the use of
myeloablative chemotherapy with autologous stem cell
transplantation in high risk or recurrent medulloblastoma,
especially in children younger than three years [94,95]. This
therapeutic strategy might also reduce the need of
craniospinal radiation in this high-risk group and may in that
way decrease the risk of intellectual decline [94]. Finally, the
age limit for craniospinal therapy remains an important issue,
since intellectual decline is clearly more pronounced in
patients with younger age at diagnosis
[55,58,59,74,77,79,81,85]. Chemotherapy regiments are
indeed evolving in this group. Delaying craniospinal
radiotherapy until the age of six might become more and more
feasible. Large international clinical studies will be necessary
to demonstrate the efficacy, safety and impact on long-term
effects of this approach.
Finally, although motor rehabilitation received a lot of
attention in the past, standardized cognitive trainings and
rehabilitation is currently lacking. Nevertheless, multiple
methods (training processing speed, attention, memory etc.)
recently seemed beneficial [96,97]. Also, more and more
attention is given to computerized trainings, including recent
developments in virtual reality applications [98]. However,
results of these methods are still to be waited for.
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Conclusion
Posterior fossa tumors in children constitute a
heterogeneous group of neoplasms, with medulloblastoma,
astrocytoma and ependymoma as the predominant tumor
types. Advances in treatment over the last decades have led
towards better survival, but also gave rise to the development
of long-term treatment-related sequelae. This study gave an
overview of different somatic, neuropsychological and
psychosocial effects linked to the different treatment
regiments. Medulloblastoma survivors suffered the highest
treatment-related morbidity, with increased risk due to
craniospinal radiotherapy, higher radiation dose, younger age
at diagnosis and preoperative hydrocephalus. As a conclusion,
long-term treatment-related sequelae should receive sufficient
attention of all specialists involved (neurosurgeons,
radiotherapists and oncologists). Treatments highly require
advancements to preventively lower neurotoxicity, as well as
rehabilitation in patients after treatment.
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